<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Process" Owner="NLM">        <PMID Version="1">30268525</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>16</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1095-6859</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>151</Volume>                    <Issue>2</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>11</Month>                    </PubDate>                </JournalIssue>                <Title>Gynecologic oncology</Title>                <ISOAbbreviation>Gynecol. Oncol.</ISOAbbreviation>            </Journal>            <ArticleTitle>Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States.</ArticleTitle>            <Pagination>                <MedlinePgn>190-195</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S0090-8258(18)31176-4</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ygyno.2018.09.003</ELocationID>            <Abstract>                <AbstractText Label="OBJECTIVE">Real-world data on patients with cancer developing secondary malignancies such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are lacking. This study assessed the incidence and impact of select DNA-damaging therapy exposure on risk of secondary MDS and AML in patients with ovarian cancer (OC) or breast cancer (BC).</AbstractText>                <AbstractText Label="METHODS">Adults with a first observed OC or BC diagnosis (index date) between 1/1/2000 and 6/30/2014 were identified from MarketScan® Commercial and Medicare databases. Patients had ≥12 months of pre-index and ≥1 month of post-index continuous health plan enrollment. Incidence of MDS/AML was evaluated over a variable-length period following the index date for each cancer cohort. Risk factors for secondary MDS/AML, including duration of DNA-damaging therapy exposure, were assessed using Poisson regression.</AbstractText>                <AbstractText Label="RESULTS">Study selection criteria identified 23,862 patients with OC and 281,473 patients with BC (mean [SD] follow-up: 35.8 [31.4] and 46.0 [37.2] months, respectively). Incidence of MDS/AML was 2.77 and 1.44 per 1000 person-years among patients with OC and BC, respectively. Within both cohorts, incidence of MDS and AML was higher among patients exposed than those not exposed to select DNA-damaging therapy (alkylating agents, antimetabolites, platinum-based antineoplastic agents, and topoisomerase inhibitors). Duration of exposure to DNA-damaging therapy was a significant risk factor for developing MDS/AML during follow-up.</AbstractText>                <AbstractText Label="CONCLUSIONS">Data suggest that there is likely a background risk of secondary MDS/AML associated with use of DNA-damaging therapies in earlier lines of chemotherapy and it is elevated in subcohorts exposed to select DNA-damaging therapies.</AbstractText>                <CopyrightInformation>Copyright © 2018. Published by Elsevier Inc.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Shenolikar</LastName>                    <ForeName>Rahul</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>AstraZeneca, Gaithersburg, MD, USA. Electronic address: rahul.shenolikar@astrazeneca.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Durden</LastName>                    <ForeName>Emily</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Truven Health Analytics, an IBM Company, Bethesda, MD, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Meyer</LastName>                    <ForeName>Nicole</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Truven Health Analytics, an IBM Company, Bethesda, MD, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lenhart</LastName>                    <ForeName>Gregory</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Truven Health Analytics, an IBM Company, Bethesda, MD, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Moore</LastName>                    <ForeName>Kathleen</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>27</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Gynecol Oncol</MedlineTA>            <NlmUniqueID>0365304</NlmUniqueID>            <ISSNLinking>0090-8258</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="Y">Acute myeloid leukemia</Keyword>            <Keyword MajorTopicYN="Y">Breast cancer</Keyword>            <Keyword MajorTopicYN="Y">Myelodysplastic syndrome</Keyword>            <Keyword MajorTopicYN="Y">Olaparib</Keyword>            <Keyword MajorTopicYN="Y">Ovarian cancer</Keyword>            <Keyword MajorTopicYN="Y">Real world</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>03</Month>                <Day>23</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>08</Month>                <Day>09</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>03</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>1</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>1</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>1</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30268525</ArticleId>            <ArticleId IdType="pii">S0090-8258(18)31176-4</ArticleId>            <ArticleId IdType="doi">10.1016/j.ygyno.2018.09.003</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>